1. Volume 76, Issue 1, Pages 73-81 (July 2019)
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract 
Cora N. Sternberg, Yohann Loriot, Nicholas James, Ernest Choy, Daniel Castellano, Fernando Lopez-Rios, Giuseppe L. Banna, Ugo De Giorgi, Cristina Masini, Aristotelis Bamias, Xavier Garcia del Muro, Ignacio Duran, Thomas Powles, Marija Gamulin, Friedemann Zengerling, Lajos Geczi, Craig Gedye, Sabine de Ducla, Simon Fear, Axel S. Merseburger 
European Urology 
Volume 76, Issue 1, Pages (July 2019)
DOI: /j.eururo
Copyright © 2019 The Author(s) Terms and Conditions

2. Fig. 1
Efficacy in the intent-to-treat population: (A) overall survival (OS), (B) progression-free survival (PFS), and (C) duration of response. CI=confidence interval.
European Urology  , 73-81DOI: ( /j.eururo )
Copyright © 2019 The Author(s) Terms and Conditions

3. Fig. 2
Efficacy in the overall population and prespecified difficult-to-treat subgroups. CNS=central nervous system; ECOG PS=Eastern Cooperative Oncology Group performance status; OS=overall survival.
European Urology  , 73-81DOI: ( /j.eururo )
Copyright © 2019 The Author(s) Terms and Conditions